CCL5 and infection: Consistent with the alleviated host response to infection in the case of MitoQ treatment, we observed significantly (p<0.01) reduced levels of systemic RANTES, a chemokine highly chemoattractant for the inflammatory infiltrate, upon MitoQ administration throughout (Figure 9G).